Dr. Susan Anton has been appointed director of Epidemiology and Risk Management Practice, ICON Late Phase & Outcomes Research. Dr. Anton has more than 25 years of experience leading international epidemiologic, health economic, and outcomes research, and other market access initiatives. She joins the company from Boehringer Ingelheim, where she was director of U.S. Medical Outcomes Research and Registries. Prior to BI, Dr. Anton directed health economic, epidemiologic and outcomes research efforts across therapeutic areas at Bristol-Myers Squibb.
 
Dr. Pui Leung has been appointed senior clinical research physician at ICON’s Clinical Pharmacology Unit in Manchester, UK. Dr. Leung has more than 23 years of hospital and pharmaceutical industry experience in a variety of medical specialties including diabetes, endocrinology and general medicine. Prior to ICON, Dr. Leung spent 10 years as a senior Phase I Clinical Research Physician at two UK CROs and has been principal investigator in many trials.